Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

• Published in: British journal of clinical pharmacology Vol. 54; no. 3; pp. 309 - 319
• Main Authors: Kosoglou, Teddy, Meyer, Ingo, Veltri, Enrico P., Statkevich, Paul, Yang, Bo, Zhu, Yali, Mellars, Lillian, Maxwell, Stephen E., Patrick, James E., Cutler, David L., Batra, Vijay K., Affrime, Melton B.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01-09-2002; Blackwell Science Inc
• Subjects: Administration, Oral; Adult; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - pharmacokinetics; Anticholesteremic Agents - pharmacology; Azetidines - administration & dosage; Azetidines - pharmacokinetics; Azetidines - pharmacology; Biological Availability; Body Mass Index; cholesterol absorption inhibitor; Cholesterol, LDL - antagonists & inhibitors; Dose-Response Relationship, Drug; Drug Combinations; drug interaction; Drug Interactions; Drugs Interaction; Ezetimibe; Humans; hypercholesterolaemia; Male; Middle Aged; pharmacodynamics; pharmacokinetics; simvastatin; Simvastatin - administration & dosage; Simvastatin - pharmacokinetics; Simvastatin - pharmacology
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1046/j.1365-2125.2002.01633.x

Aims  The primary aims of these two single‐centre, randomized, evaluator‐blind, placebo/positive‐controlled, parallel‐group studies were to evaluate the potential for pharmacodynamic and pharmacokinetic interaction between ezetimibe 0.25, 1, or 10 mg and simvastatin 10 mg (Study 1), and a pharmacodynamic interaction between ezetimibe 10 mg and simvastatin 20 mg (Study 2). Evaluation of the tolerance of the coadministration of ezetimibe and simvastatin was a secondary objective.
Methods  Eighty‐two healthy men with low‐density lipoprotein cholesterol (LDL‐C) ≥130 mg dl−1 received study drug once daily in the morning for 14 days. In Study 1 (n=58), five groups of 11–12 subjects received simvastatin 10 mg alone, or with ezetimibe 0.25, 1, or 10 mg or placebo. In Study 2 (n=24), three groups of eight subjects received simvastatin 20 mg alone, ezetimibe 10 mg alone, or the combination. Blood samples were collected to measure serum lipids in both studies. Steady‐state pharmacokinetics of simvastatin and its β‐hydroxy metabolite were evaluated in Study 1 only.
Results  In both studies, reported side‐effects were generally mild, nonspecific, and similar among treatment groups. In Study 1, there were no indications of pharmacokinetic interactions between simvastatin and ezetimibe. All active treatments caused statistically significant (P<0.01) decreases in LDL‐C concentration vs placebo from baseline to day 14. The coadministration of ezetimibe and simvastatin caused a dose‐dependent reduction in LDL‐C and total cholesterol, with no apparent effect on high‐density lipoprotein cholesterol (HDL‐C) or triglycerides. The coadministration of ezetimibe 10 mg and simvastatin 10 mg or 20 mg caused a statistically (P<0.01) greater percentage reduction (mean −17%, 95% CI −27.7, −6.2, and −18%, −28.4, −7.4, respectively) in LDL‐C than simvastatin alone.
Conclusions  The coadministration of ezetimibe at doses up to 10 mg with simvastatin 10 or 20 mg daily was well tolerated and caused a significant additive reduction in LDL‐C compared with simvastatin alone. Additional clinical studies to assess the efficacy and safety of coadministration of ezetimibe and simvastatin are warranted.